Back to Journals » Clinical Ophthalmology » Volume 4

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients

Authors Patil AJ, Sharma A, Kenney MC, Kuppermann B

Published 1 March 2010 Volume 2010:4 Pages 111—119

DOI https://doi.org/10.2147/OPTH.S3248

Review by Single-blind

Peer reviewer comments 1

A Jayaprakash Patil1,2,3, Ashish Sharma1,4, M Cristina Kenney1, Baruch D Kuppermann1

1Department of Ophthalmology, Gavin S Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA; 2Department of Ophthalmology, Summa Health System, Akron, OH, USA; 3Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH, USA; 4Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USA

Abstract: Oral valganciclovir is a new and highly efficacious alternative to the chronic administration of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in HIV-infected patients. In addition to its excellent bioavailability and favorable pharmacokinetic profile, valganciclovir has also proved cost effective and is the most widely used drug in the armamentarium for the treatment of CMV retinitis. Valganciclovir is a prodrug of ganciclovir, the erstwhile commonly used therapy. In March 2001, the US Food and Drug Administration approved valganciclovir for the induction and maintenance treatment of CMV disease, including CMV retinitis. Valganciclvoir has compared favorably with both oral and intravenous treatments for induction and maintenance therapy with ganciclovir. The reduced pill burden and the ease of oral administration has helped avoid the risks associated with intravenous therapy. The most serious adverse event is neutropenia, which makes the patient susceptible to infections. In the current review, we have compiled all the available evidence-based information on valganciclovir.
Keywords: CMV retinitis, ganciclovir, valganciclovir

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema

Rocío Herrero-Vanrell, Jose Augusto Cardillo, Baruch D Kuppermann

Clinical Ophthalmology 2011, 5:139-146

Published Date: 1 February 2011

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010